Answers are grounded in this paper and cite their sources.
This JACC Scientific Statement outlines the current challenges and future needs for accurate, lifespan-spanning clinical risk assessment in congenital heart disease.
Congenital heart disease (CHD) comprises a range of structural anomalies, each with a unique natural history, evolving treatment strategies, and distinct long-term consequences. Current prediction models are challenged by generalizability, limited validation, and questionable application to extended follow-up periods. In this JACC Scientific Statement, we tackle the difficulty of risk measurement across the lifespan. We appraise current and future risk measurement frameworks and describe domains of risk specific to CHD. Risk of adverse outcomes varies with age, sex, genetics, era, socioeconomic status, behavior, and comorbidities as they evolve through the lifespan and across care settings. Emerging technologies and approaches promise to improve risk assessment, but there is also need for large, longitudinal, representative, prospective CHD cohorts with multidimensional data and consensus-driven methodologies to provide insight into time-varying risk. Communication of risk, particularly with patients and their families, poses a separate and equally important challenge, and best practices are reviewed.
No takes yet. Share an insight, caveat, or question.
Opotowsky et al. (2024) conducted a review in Congenital heart disease. Risk assessment and prediction frameworks was evaluated. This scientific statement reviews risk measurement frameworks for congenital heart disease across the lifespan, emphasizing the need for large, longitudinal cohorts to improve risk assessment.
Synapse has enriched 10 related papers. Consider them for comparative context: